International GLP-1 Sourcing Risks During Shortage
As a physician, drug supply disruptions poses real clinical challenges that are more serious than simple frustration. I’m explaining what you must be aware of.
How Shortages Affect Health
Forced medication discontinuation create documented health consequences:
What Happens Physiologically
If you suddenly discontinue their weight loss drug:
- Weight rebound: Data indicates 67% of lost weight is regained within 6–12 months of stopping
- Glycemic control loss: For diabetic patients, glucose control worsens rapidly
- Appetite return: The hunger-reducing effects stops soon after drug washout
- Emotional consequences: Depression, loss of control, and relationship with food disruption may develop
Medical Approaches
Dose Modification
If the prescribed strength aren’t available:
- Dose reduction: Using a reduced dose continues some therapeutic benefit and avoids abrupt cessation
- Extended intervals: Administering the available dose at extended intervals instead of every 7 days — suboptimal but better than nothing
- Dose splitting: When feasible, splitting a higher dose into smaller administrations
Alternative Medications
When a specific medication is completely unavailable:
- Switching between drug classes: Requires thoughtful cross-titration — the pharmacology differs
- Injectable ↔ oral: Ozempic to Rybelsus is possible but absorption is different
- Other weight loss medications: Other pharmacotherapy as temporary bridging until GLP-1s return
Talking to Patients
For clinicians:
- Be transparent about timeline uncertainty — patients deserve realistic expectations
- Document everything — any changes due to supply should be documented
- Create a protocol for action steps if availability is disrupted
- Increase follow-up during shortage-related changes — people with interrupted therapy require closer monitoring
Systemic Issues
Pharmaceutical supply disruptions have existed for decades — but the weight loss drug shortage is unprecedented in its magnitude.
Structural changes require:
- Expanded manufacturing — already underway but still ramping up
- Smarter supply chains — fair distribution
- Policy adaptation — including compounding rules that respond to market realities
In the meantime, providers and patients have to manage these difficult conditions with clear communication.